Multiple myeloma/hypercalcemia

Arthritis Research and Therapy

Volumn 9, Issue SUPPL.1, 2007, Pages

  Oyajobi, Babatunde O ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMGN 0007; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM ION; CLODRONIC ACID; CORTICOSTEROID; DENOSUMAB; GENE PRODUCT; IBANDRONIC ACID; IIC3; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PROTEIN DKK1; PROTEIN INHIBITOR; RECOMBINANT OSTEOPROTEGERIN; SODIUM CHLORIDE; ZOLEDRONIC ACID;

BONE DESTRUCTION; BONE DISEASE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CELL INVASION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; MYELOMA BONE DISEASE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; BONE RESORPTION; HUMANS; HYPERCALCEMIA; MULTIPLE MYELOMA; RANK LIGAND;

EID: 34548384769     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2168     Document Type: Review

References (45)

1. Oyajobi BO Mundy GR Pathophysiology of myeloma bone disease Multiple Myeloma and Related Disorders London, UK: Arnold Gahrton G, Durie BGM, Samson DS 2, 2004:74-88.
2. Garcia-Sanz R Orfão A Gonzalez M Tabernero MD Bladé J Moro MJ Fernandez-Calvo J Sanz MA Perez-Simon JA Rasillo A Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics Blood 1999, 93:1032-1037. 9920853
3. Tuttle KR Kunau RT Loveridge N Mundy GR Altered renal calcium handling in hypercalcemia of malignancy J Am Soc Nephrol 1991, 2:191-199. 1954331
4. Durie BGM Salmon SE Mundy GR Relation of osteoclast activating factor production to the extent of bone disease in multiple myeloma Br J Haematol 1981, 47:21-30. 7437344
5. Oyajobi BO Traianedes K Yoneda T Mundy GR Expression of RANK ligand (RANKL) by myeloma cells requires binding to bone marrow stromal cells via an α4β1-VCAM-1 interaction Bone 1998, (Suppl):S180.
6. Pearse RN Sordillo EM Yaccoby S Wong BR Liau DF Colman N Michaeli J Epstein J Choi Y Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proc Natl Acad Sci USA 2001, 98:11581-11586. 58772 11562486 10.1073/ pnas.201394498
7. Giuliani N Bataille R Mancini C Lazarretti M Barille S Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment Blood 2001, 98:3527-3533. 10.1182/ blood.V98.13.3527 11739153
8. Roux S Meignin V Quillard J Meduri G Guiochon-Mantel A Fermand J-P Milgrom E Mariette X RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma Br J Haematol 2002, 117:86-92. 10.1046/j.1365-2141.2002.03417.x 11918537
9. Farrugia AN Atkins GJ To LB Pan B Horvath N Findlay DM Bardy A Zannettino AC Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo Cancer Res 2003. 63:5438-5445. 14500379
10. Croucher PI Shipman CM Lippitt J Perry M Asosingh K Hijzen A Brabbs AC van Beek EJR Holen I Skerry TM Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma Blood 2001, 98:3534-3540. 10.1182/blood.V98.13.3534 11739154
11. Sezer O Heider U Jakob C Zavrski I Eucker J Possinger K Sers C Krenn V Immunocytochemistry reveals RANKL expression of myeloma cells Blood 2002, 99:4646-4647. 10.1182/blood-2002-01-0148 12066787
12. Sezer O Heider U Jakob C Eucker J Possinger K Human bone marrow myeloma cells express RANKL J Clin Oncol 2002, 20:353-354. 11773196
13. Lai FP Cole-Sinclair M Cheng WJ Quinn JM Gillespie MT Sentry JW Schneider HG Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation Br J Haematol 2004, 126:192-201. 10.1111/ j.1365-2141.2004.05018.x 15238139
14. Roux S Mariette X The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK ligand expression Leuk Lymphoma 2004, 45:1111-1118. 10.1080/ 10428194310001593193 15359989
15. Oyajobi BO Williams PJ Traianedes K Yoneda T Anderson DM Mundy GR Efficacy of a genetically-engineered soluble Receptor Activator of NF-κB (RANK) fusion protein on bone resorption in vitro and in vivo Cancer 2000, (Suppl):3093.
16. Yaccoby S Pearse RN Johnson CL Barlogie B Choi Y Epstein J Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity Br J Haematol 2002, 116:278-290. 10.1046/j.1365-2141.2002.03257.x 11841428
17. Vanderkerken K De Leenheer E Shipman CM Asosingh K Willems A Van Camp B Croucher P Recombinant osteoprotegerin decreases tumor burden and increases survival in a mouse model of multiple myeloma Cancer Res 2003, 63:287-289. 12543775
18. Oyajobi BO Anderson DM Traianedes K Williams PJ Yoneda T Mundy GR Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy Cancer Res 2001, 61:2572-2578. 11289133
19. Mori Y Shimizu N Dallas M Niewolna M Williams PJ Mundy GR Yoneda T Anti-α4 integrin antibody suppresses the development of myeloma and associated osteolysis Blood 2004, 104:2149-2154. 10.1182/ blood-2004-01-0236 15138161
20. Standal T Seidel C Hjertner O Plesner T Sanderson RD Waage A Borset M Sundan A Osteoprotegerin is bound, internalized and degraded by multiple myeloma cells Blood 2002, 100:3002-3007. 10.1182/blood-2002-04-1190 12351414
21. Seidel C Hjertner O Abildgaard N Heickendorf L Hjorth M Westin J Nielsen JL Hjorth-Hansen H Waagew A Sundan A Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease Blood 2001, 98:2269-2271. 10.1182/blood.V98.7.2269 11568016
22. Oyajobi BO Franchin G Williams PJ Pulkrabek D Gupta A Munoz S Grubbs B Zhao M Chen D Sherry B Mundy GR Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease Blood 2003, 102:311-319. 10.1182/ blood-2002-12-3905 12649140
23. Choi SJ Cruz JC Craig F Chung H Devlin RD Roodman GD Alsina M Macrophage inflammatory protein-1α is a potential osteoclast stimulatory factor in multiple myeloma Blood 2000, 96:671-675. 10887133
24. Abe M Hiura K Wilde J Moriyama K Hashimoto T Ozaki S Wakatsuki S Kosaka M Kido S Inoue D Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma Blood 2002, 100:2195-2202. 12200385
25. Hashimoto T Abe M Oshima T Shibata H Ozaki S Inoue D Matsumoto T Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma Br J Haematol 2004, 125:38-41. 10.1111/ j.1365-2141.2004.04864.x 15015966
26. Uneda S Hata H Matsuno F Harada N Mitsuya Y Kawano F Mitsuya H Macrophage inflammatory protein-1α is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM Br J Haematol 2003, 120:53-55. 10.1046/ j.1365-2141.2003.04040.x 12492576
27. Terpos E Politou M Szydlo R Goldman JM Apperley JF Rahemtulla A Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma Br J Haematol 2003, 123:106-109. 10.1046/ j.1365-2141.2003.04561.x 14510950
28. Taichman RS Reilly MJ Matthew LS Human osteoblast-like cells and osteosarcoma cell lines synthesize macrophage inhibitory protein 1α in response to interleukin 1β and tumour necrosis factor-α stimulation in vitro Br J Haematol 2000, 108:275-283. 10.1046/j.1365-2141.2000.01873.x 10691855
29. Lichtenstein A Berenson J Norman D Chang MP Carlile A Production of cytokines by bone marrow cells obtained from patients with multiple myeloma Blood 1989, 74:1266-1273. 2475182
30. Oba Y Lee JW Ehrlich LA Chung HY Jelinek DF Callander NS Horuk R Choi SJ Roodman GD MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells Exp Hematol 2005, 33:272-278. 10.1016/j.exphem.2004.11.015 15730850
31. Menu E De Leenheer E De Raeve H Coulton L Imanishi T Miyashita K Van Valckenborgh E Van Riet I Van Camp B Horuk R Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: A study in the 5TMM model Clin Exp Metastasis 2006, 23:291-300. 10.1007/s10585-006-9038-6 17086356
32. Okada Y Tsukada J Nakano K Tonai S Mine S Tanaka Y Macrophage inflammatory protein-1α induces hypercalcemia in adult T-cell leukemia J Bone Miner Res 2004, 19:1105-1111. 10.1359/JBMR.040314 15176993
33. Tian E Zhan F Walker R Rasmussen E Ma Y Barlogie B Shaughnessy JD Jr The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med 2003, 349:2483-2494. 10.1056/NEJMoa030847 14695408
34. Spencer GJ Utting JC Etheridge SL Arnett TR Genever PG Wnt signalling in osteoblasts regulates expression of the receptor activator of NF-κB ligand and inhibits osteoclastogenesis in vitro J Cell Sci 2006, 119:1283-1296. 10.1242/jcs.02883 16522681
35. Oyajobi BO Gupta A Flores A Wideman C Shipman C Mundy GR Garrett IR Dkk1 modulates osteoclastogenesis and bone resorption: Implications for myeloma bone disease J Bone Miner Res 2005, (Suppl 1):S32.
36. Yaccoby S Ling W Zhan F Walker R Barlogie B Shaughnessy JD Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood 2007, 109:2106-2011. 1801040 17068150 10.1182/blood-2006-09-047712
37. Stewart AF Hypercalcemia associated with cancer N Engl J Med 2005, 352:373-379. 10.1056/NEJMcp042806 15673803
38. Body JJ Bisphosphonates for malignancy-related bone disease: Current status, future developments Support Care Cancer 2006, 14:408-418. 10.1007/s00520-005-0913-5 16450087
39. Bell R Efficacy of ibandronate in metastatic bone disease: Review of clinical data Oncologist 2005, (Suppl 1):8-13. 10.1634/ theoncologist.10-90001-8
40. Rosen LS Gordon D Antonio BS Kaminski M Howell A Belch A Mackey JA Apffelstaedt J Hussein M Coleman RE Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial Cancer J 2001, 7:377-387. 11693896
41. Morony S Warmington K Adamu S Asuncion F Geng Z Grisanti M Tan HL Capparelli C Starnes C Weimann B The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy Endocrinology 2005, 146:3235-3243. 10.1210/en.2004-1583 15845617
42. Body JJ Facon T Coleman RE Lipton A Geurs F Fan M Holloway D Peterson MC Bekker PJ A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 2006, 12:1221-1228. 10.1158/1078-0432.CCR-05-1933 16489077
43. ClinicalTrials.gov http://www.clinicaltrials.gov
44. Liang M Mallari C Rosser M Ng HP May K Monahan S Bauman JG Islam I Ghannam A Buckman B Identification and characterization of a potent, selective and orally active antagonist of the CC chemokine receptor-1 J Biol Chem 2000, 275:19000-19008. 10.1074/jbc.M001222200 10748002
45. Nair SR Pearson SB Images in clinical medicine. Pathologic fracture and lytic lesions in multiple myeloma N Engl J Med 2004, 351:1874. 10.1056/ NEJMicm031146 15509820